Glaucoma, Neovascular clinical trials
The registry lists 39 studies for Glaucoma, Neovascular across more than 10 countries. 5 are recruiting or about to start. 24 of them are mainly about Glaucoma, Neovascular (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20.
Get an email when these change. Save the Glaucoma, Neovascular studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Bayer (3) · Zhongnan Hospital (3) · Ruijin Hospital (2) · Federal University of São Paulo (2) · Siriraj Hospital (2) · Prince of Songkla University (2) · Ain Shams University (2) · Wills Eye (2)
What is being tested here
Drugs under test in Glaucoma, Neovascular studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ranibizumab | 0 | 2 | 8 |
| Aflibercept | 0 | 2 | 4 |
| Bevacizumab | 0 | 0 | 1 |
| Mitomycin | 0 | 0 | 1 |
| Triamcinolone Acetonide | 0 | 1 | 1 |
| Triamcinolone | 0 | 1 | 1 |
| GS 101 | 0 | 1 | 1 |
| Travoprost | 0 | 0 | 1 |
Drug classes tested here Angiogenesis inhibitors 13
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
Who these studies take
Of the 3 Glaucoma, Neovascular studies recruiting now, 3 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 3 (100%) | 3 (100%) |
| 85 | 3 (100%) | 3 (100%) |
Across all 39 studies, recruiting or not: 10% stop at 75 or younger and 5% at 65; 10% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Efficacy and Safety of Minimally Invasive Suprachoroidal DrainageOct 20, 2026NCT07882511
Studies
Recruiting first, then most recently updated. Showing 39 of 39. search them.
- Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular GlaucomaRecruitingNCT077229101 country
- Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)RecruitingNCT045196191 country
- Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCTRecruitingNCT03648814Not applicable1 country
- MicroPulse TLT - UK StudyNot yet recruitingNCT05593354
- INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma RegisterEnrolling by invitationNCT043816111 country
- Efficacy and Safety of Minimally Invasive Suprachoroidal DrainageCompletedNCT078825111 country
- Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular GlaucomaActive, not recruitingNCT07201415Not applicable1 country
- Clinical Characteristics of Neovascular GlaucomaCompletedNCT071778071 country
- Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular GlaucomaActive, not recruitingNCT05316142Not applicable1 country
- KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) TrialActive, not recruitingNCT04844619Phase 11 country
- Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular GlaucomaTerminatedNCT02260219Not applicable
- A Study on the Treatment Strategy of NVG Secondary to PDRCompletedNCT05156021Not applicable1 country
- Ahmed Glaucoma Valve Surgery With Mitomycin-CCompletedNCT02805257Phase 24 countries
- Use of Intravitreal Aflibercept Injection for Neovascular GlaucomaCompletedNCT01711879Not applicable1 country
- Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled GlaucomaCompletedNCT03187418Not applicable1 country
- Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular GlaucomaCompletedNCT04970251Not applicable1 country
- Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular GlaucomaCompletedNCT01922154Phase 41 country
- Comparison of Silicone and Porous Plate Ahmed Glaucoma ValvesCompletedNCT01883856Not applicable1 country
- the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory GlaucomaCompletedNCT01774227Not applicable1 country
- Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also StudiedCompletedNCT03639675Phase 31 country
- Lucentis for New Onset Neovascular GlaucomaWithdrawnNCT00727038Phase 1/2
- Baerveldt (BGI) Valve Versus Ahmed(AGV) Valve in Management of Difficult Glaucoma CasesCompletedNCT04215575Not applicable
- The Outcome of Ahmed Glaucoma Valve in Difficult Glaucoma CasesCompletedNCT04214847Not applicable
- An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 31 country
- Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?CompletedNCT00853905Phase 2/31 country
- The Effect of Conbercept Injection Through Different Routes for Neovascular GlaucomaCompletedNCT03154892Not applicable1 country
- Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsCompletedNCT02396316Phase 31 country
- Oculusgen (Ologen) Glaucoma MMC Control in EstoniaCompletedNCT00524758Phase 31 country
- Analysis of Aqueous and Vitreous HumorStatus unknownNCT02067013Phase 21 country
- Ranibizumab in Combination With Proton Beam Irradiation for Choroidal MelanomaCompletedNCT00765921Phase 11 country
- Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device TubeTerminatedNCT01301378Not applicable1 country
- Trial of Aganirsen in iCRVO Patients at Risk of Developing NVGStatus unknownNCT02947867Phase 2/3
- Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled StudyStatus unknownNCT02914626Phase 3
- Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular GlaucomaCompletedNCT02647515Phase 4
- Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular GlaucomaCompletedNCT01370135Not applicable1 country
- Effects of Travoprost on Neovascular GlaucomaWithdrawnNCT00441181Not applicable1 country
- Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory GlaucomaStatus unknownNCT01128699Phase 31 country
- Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular GlaucomaCompletedNCT01051583Phase 21 country
- Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone InjectionStatus unknownNCT00491712Not applicable1 country